NEW YORK and PETACH TIKVAH, Israel, Aug. 6, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it will report second quarter 2015 financial results on Thursday, August 13, 2015. The Company will issue a press release before the market opens and will host a conference call at 8:00am Eastern Time to discuss the financial results and answer questions.
Conference Call & Webcast
Thursday, August 13, 2015 at 8:00 a.m. EST/5:00 a.m. PST
Domestic: 888-329-8893 Israel: 1 80 924 5906 International: 719-325-2354 Conference ID: 5122591 Webcast: http://public.viavid.com/player/index.php?id=115681
Replay will be available through August 27, 2015
Domestic: 877-870-5176 International: 858-384-5517 Conference ID: 5122591
About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. NurOwn® has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States. For more information, visit the company's website at www.brainstorm-cell.com.
SOURCE BrainStorm Cell Therapeutics Inc.